The difficulties of 2020 have placed a spotlight on life science innovation and the importance of having the right infrastructure and ability to bringing critical innovation to the market. In recognition of her exceptional work and leadership of Johnson & Johnson Innovation’s efforts in China, Fortune China has named Dan Wang, Head of Johnson & Johnson Innovation Asia Pacific, to its China Most Powerful Women list for 2020.
Innovate in Time of Uncertainty
The Fortune China Most Powerful Women 2020 list was launched this year for the first time to recognize extraordinary female leaders making remarkable strides in their fields in China during these unprecedented times.
With more than 20 years of experience in the healthcare industry, Dan is responsible for managing a portfolio of collaboration and deal execution spanning across all three business sectors of medical devices, pharmaceuticals and consumer health. Despite the pandemic, the Johnson & Johnson Asia Pacific Innovation Center has facilitated a record number of collaborations spanning multiple areas, including disruptive health technologies and new business model innovations to accelerate Johnson & Johnson’s R&D pipeline for potentially transformative solutions for patients and consumers.
Will Song, Global Senior Vice President, China Chairman, Johnson & Johnson, commented: “We are beyond delighted for Dan Wang’s recognition and commend her for being the first-ever Johnson & Johnson leader to be listed by Fortune China in this category. Her strong leadership has opened up several opportunities to advance innovative healthcare solutions and technologies for patients and consumers in China and the Asia Pacific, and we look forward to continuously work together with our partners in China to accelerate innovation and truly change the trajectory of health for humanity.”
Johnson & Johnson is confident about the long-term development of the Chinese market and will continue to drive high-quality development through innovation. Johnson & Johnson Innovation does this through its Asia Pacific Innovation Center, along with JLABS @ Shanghai, the world’s largest Johnson & Johnson Innovation incubator, the company’s corporate venture arm JJDC, Lung Cancer Initiative China and sector R&D teams.
Redoubling this commitment, Johnson & Johnson will continue to invest in China as one of the leading global business development engines by working with strategic partners across industries to build a "healthy China" and deliver yet more healthcare innovation from China to the world.